Marcel Tanner

Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland.

Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland.

Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland.

Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Malaria Consortium is a non-profit organization that specializes in preventing, controlling, and treating malaria and other communicable diseases among vulnerable populations. The non-profit company is based in London, UK. Malaria Consortium's evidence-based programs combat targeted diseases and promote universal health coverage in Africa and Asia. The British company was founded in 2003 by Sylvia Meek, and the CEO is Charles Nelson.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Malaria Consortium is a non-profit organization that specializes in preventing, controlling, and treating malaria and other communicable diseases among vulnerable populations. The non-profit company is based in London, UK. Malaria Consortium's evidence-based programs combat targeted diseases and promote universal health coverage in Africa and Asia. The British company was founded in 2003 by Sylvia Meek, and the CEO is Charles Nelson.

Malaria Consortium is a non-profit organization that specializes in preventing, controlling, and treating malaria and other communicable diseases among vulnerable populations. The non-profit company is based in London, UK. Malaria Consortium's evidence-based programs combat targeted diseases and promote universal health coverage in Africa and Asia. The British company was founded in 2003 by Sylvia Meek, and the CEO is Charles Nelson.

Malaria Consortium is a non-profit organization that specializes in preventing, controlling, and treating malaria and other communicable diseases among vulnerable populations. The non-profit company is based in London, UK. Malaria Consortium's evidence-based programs combat targeted diseases and promote universal health coverage in Africa and Asia. The British company was founded in 2003 by Sylvia Meek, and the CEO is Charles Nelson.

Malaria Consortium is a non-profit organization that specializes in preventing, controlling, and treating malaria and other communicable diseases among vulnerable populations. The non-profit company is based in London, UK. Malaria Consortium's evidence-based programs combat targeted diseases and promote universal health coverage in Africa and Asia. The British company was founded in 2003 by Sylvia Meek, and the CEO is Charles Nelson.

Malaria Consortium is a non-profit organization that specializes in preventing, controlling, and treating malaria and other communicable diseases among vulnerable populations. The non-profit company is based in London, UK. Malaria Consortium's evidence-based programs combat targeted diseases and promote universal health coverage in Africa and Asia. The British company was founded in 2003 by Sylvia Meek, and the CEO is Charles Nelson.

Malaria Consortium is a non-profit organization that specializes in preventing, controlling, and treating malaria and other communicable diseases among vulnerable populations. The non-profit company is based in London, UK. Malaria Consortium's evidence-based programs combat targeted diseases and promote universal health coverage in Africa and Asia. The British company was founded in 2003 by Sylvia Meek, and the CEO is Charles Nelson.

Malaria Consortium is a non-profit organization that specializes in preventing, controlling, and treating malaria and other communicable diseases among vulnerable populations. The non-profit company is based in London, UK. Malaria Consortium's evidence-based programs combat targeted diseases and promote universal health coverage in Africa and Asia. The British company was founded in 2003 by Sylvia Meek, and the CEO is Charles Nelson.

Malaria Consortium is a non-profit organization that specializes in preventing, controlling, and treating malaria and other communicable diseases among vulnerable populations. The non-profit company is based in London, UK. Malaria Consortium's evidence-based programs combat targeted diseases and promote universal health coverage in Africa and Asia. The British company was founded in 2003 by Sylvia Meek, and the CEO is Charles Nelson.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.